keyword
MENU ▼
Read by QxMD icon Read
search

Kopyt

keyword
https://www.readbyqxmd.com/read/27698467/electrodynamic-study-of-yig-filters-and-resonators
#1
Jerzy Krupka, Bartlomiej Salski, Pawel Kopyt, Wojciech Gwarek
Numerical solutions of coupled Maxwell and Landau-Lifshitz-Gilbert equations for a magnetized yttrium iron garnet (YIG) sphere acting as a one-stage filter are presented. The filter is analysed using finite-difference time-domain technique. Contrary to the state of the art, the study shows that the maximum electromagnetic power transmission through the YIG filter occurs at the frequency of the magnetic plasmon resonance with the effective permeability of the gyromagnetic medium μr ≈ -2, and not at a ferromagnetic resonance frequency...
October 4, 2016: Scientific Reports
https://www.readbyqxmd.com/read/26832258/improvement-of-terahertz-field-effect-transistor-detectors-by-substrate-thinning-and-radiation-losses-reduction
#2
Dominique Coquillat, Jacek Marczewski, Pawel Kopyt, Nina Dyakonova, Benoit Giffard, Wojciech Knap
Phenomena of the radiation coupling to the field effect transistors based terahertz (THz) detectors are studied. We show that in the case of planar metal antennas a significant portion of incoming radiation, instead of being coupled to the transistors, is coupled to an antenna substrate leading to responsivity losses and/or cross-talk effects in the field effect based THz detector arrays. Experimental and theoretical investigations of the responsivity versus substrate thickness are performed. They clearly show how to minimize the losses by the detector/ array substrate thinning...
January 11, 2016: Optics Express
https://www.readbyqxmd.com/read/26177089/a-prospective-cohort-study-of-mineral-metabolism-after-kidney-transplantation
#3
MULTICENTER STUDY
Myles Wolf, Matthew R Weir, Nelson Kopyt, Roslyn B Mannon, Jon Von Visger, Hongjie Deng, Susan Yue, Flavio Vincenti
BACKGROUND: Kidney transplantation corrects or improves many complications of chronic kidney disease, but its impact on disordered mineral metabolism is incompletely understood. METHODS: We performed a multicenter, prospective, observational cohort study of 246 kidney transplant recipients in the United States to investigate the evolution of mineral metabolism from pretransplant through the first year after transplantation. Participants were enrolled into 2 strata defined by their pretransplant levels of parathyroid hormone (PTH), low PTH (>65 to ≤300 pg/mL; n = 112), and high PTH (>300 pg/mL; n = 134) and underwent repeated, longitudinal testing for mineral metabolites...
January 2016: Transplantation
https://www.readbyqxmd.com/read/25700466/a-case-of-suppurative-peritonitis-by-a-commensal-oral-organism-kingella-denitrificans-in-an-adult-peritoneal-dialysis-patient
#4
Nelson Kopyt, Anshul Kumar, Vibha Agrawal
No abstract text is available yet for this article.
January 2015: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/23816477/pravastatin-and-cardiovascular-outcomes-stratified-by-baseline-egfr-in-the-lipid-lowering-component-of-allhat
#5
RANDOMIZED CONTROLLED TRIAL
Mahboob Rahman, Charles Baimbridge, Barry R Davis, Joshua I Barzilay, Jan N Basile, Mario A Henriquez, Anne Huml, Nelson Kopyt, Gail T Louis, Sara L Pressel, Clive Rosendorff, Sithiporn Sastrasinh, Carol Stanford
BACKGROUND/AIMS: The role of statins in preventing cardiovascular outcomes in patients with chronic kidney disease (CKD) is unclear. This paper compares cardiovascular outcomes with pravastatin vs. usual care, stratified by baseline estimated glomerular filtration rate (eGFR). METHODS: Post-hoc analyses of a prospective randomized open-label clinical trial; 10,151 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) were randomized to pravastatin 40 mg/day or usual care...
October 2013: Clinical Nephrology
https://www.readbyqxmd.com/read/23328710/efficacy-of-cinacalcet-with-low-dose-vitamin-d-in-incident-haemodialysis-subjects-with-secondary-hyperparathyroidism
#6
RANDOMIZED CONTROLLED TRIAL
Pablo Ureña-Torres, Ian Bridges, Cynthia Christiano, Serge H Cournoyer, Kerry Cooper, Mourad Farouk, Nelson P Kopyt, Mariano Rodriguez, Daniel Zehnder, Adrian Covic
BACKGROUND: Treatment with cinacalcet improves the control of secondary hyperparathyroidism (SHPT) and the achievement of calcium and phosphorus targets. Most data come from subjects receiving cinacalcet after several years of dialysis treatment. We therefore compared the efficacy of treatment with cinacalcet and low doses of active vitamin D to flexible doses of active vitamin D alone for the management of SHPT in patients recently initiating haemodialysis. METHODS: This open-label trial randomized subjects (n = 309) with parathyroid hormone (PTH) >300 pg/mL on dialysis for 3-12 months to either cinacalcet with low-dose active vitamin D, if prescribed (cinacalcet); or usual care without cinacalcet (control)...
May 2013: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/22932122/oral-lixivaptan-effectively-increases-serum-sodium-concentrations-in-outpatients-with-euvolemic-hyponatremia
#7
RANDOMIZED CONTROLLED TRIAL
William T Abraham, Guy Decaux, Richard C Josiassen, Yoram Yagil, Nelson Kopyt, Hemant P Thacker, Massimo Mannelli, Daniel G Bichet, Cesare Orlandi
Hyponatremia is the most common electrolyte disorder in clinical practice. Its incidence increases with age and it is associated with increased morbidity and mortality. Recently, the vaptans, antagonists of the arginine vasopressin pathway, have shown promise for safe treatment of hyponatremia. Here we evaluated the efficacy, safety, and tolerability of oral lixivaptan, a selective vasopressin V2-receptor antagonist, for treatment of nonhospitalized individuals with euvolemic hyponatremia (sodium less than 135 mmol/l) in a multicenter, randomized, double-blind, placebo-controlled, phase III study...
December 2012: Kidney International
https://www.readbyqxmd.com/read/19696213/simultaneous-control-of-pth-and-caxp-is-sustained-over-three-years-of-treatment-with-cinacalcet-hcl
#8
MULTICENTER STUDY
Stuart M Sprague, Pieter Evenepoel, Mario P Curzi, Maria Teresa González, Fred E Husserl, Nelson Kopyt, Lulu Ren Sterling, Chris Mix, Gordon Wong
BACKGROUND & OBJECTIVES: Chronic kidney disease (CKD) is commonly complicated by secondary hyperparathyroidism (SHPT), leading to increased risk of morbidity and mortality. SHPT is a progressive disease often requiring long-term therapy to control parathyroid hormone (PTH) and mineral imbalances. Vitamin D sterols and phosphate binders, used as traditional therapies to lower PTH and phosphorus, may provide inadequate long-term control for many dialysis patients. Cinacalcet, by simultaneously lowering PTH, calcium, phosphorus, and calcium-phosphorus levels, may maintain PTH and mineral balance in these individuals...
September 2009: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/19193820/acute-kidney-injury-new-concepts-in-definition-diagnosis-pathophysiology-and-treatment
#9
REVIEW
Michael R Lattanzio, Nelson P Kopyt
Acute kidney injury (AKI) is increasingly recognized in all fields of medical practice. Unfortunately, this syndrome has been plagued by inconsistent definitions, simplistic pathophysiologic schemas, and insensitive diagnostic tools. Recent advances in defining AKI, understanding its pathophysiology, and improving the diagnostic accuracy of the testing tools available eventually will impact disease management and clinical outcomes. Prompt recognition and treatment of AKI remain the cornerstone of clinical management for this high-mortality, high-cost syndrome...
January 2009: Journal of the American Osteopathic Association
https://www.readbyqxmd.com/read/18676075/progression-of-kidney-disease-in-moderately-hypercholesterolemic-hypertensive-patients-randomized-to-pravastatin-versus-usual-care-a-report-from-the-antihypertensive-and-lipid-lowering-treatment-to-prevent-heart-attack-trial-allhat
#10
RANDOMIZED CONTROLLED TRIAL
Mahboob Rahman, Charles Baimbridge, Barry R Davis, Joshua Barzilay, Jan N Basile, Mario A Henriquez, Anne Huml, Nelson Kopyt, Gail T Louis, Sara L Pressel, Clive Rosendorff, Sithiporn Sastrasinh, Carol Stanford et al.
BACKGROUND: Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear. STUDY DESIGN: Prospective randomized clinical trial, post hoc analyses. SETTING & PARTICIPANTS: 10,060 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) stratified by baseline estimated glomerular filtration rate (eGFR): less than 60, 60 to 89, and 90 or greater mL/min/1...
September 2008: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/18557395/coupled-electromagnetic-thermodynamic-simulations-of-microwave-heating-problems-using-the-fdtd-algorithm
#11
Paweł Kopyt, Małgorzata Celuch
A practical implementation of a hybrid simulation system capable of modeling coupled electromagnetic-thermodynamic problems typical in microwave heating is described. The paper presents two approaches to modeling such problems. Both are based on an FDTD-based commercial electromagnetic solver coupled to an external thermodynamic analysis tool required for calculations of heat diffusion. The first approach utilizes a simple FDTD-based thermal solver while in the second it is replaced by a universal commercial CFD solver...
2007: Journal of Microwave Power and Electromagnetic Energy
https://www.readbyqxmd.com/read/18084856/management-and-treatment-of-chronic-kidney-disease
#12
REVIEW
Nelson Kopyt
Estimates suggest that 30 million Americans have some degree of chronic kidney disease. By 2030, more than 2.2 million people will require treatment for end-stage renal disease, causing a significant impact on healthcare costs in the United States.
November 2007: Nurse Practitioner
https://www.readbyqxmd.com/read/16585380/chronic-kidney-disease-the-new-silent-killer
#13
COMPARATIVE STUDY
Nelson P Kopyt
No abstract text is available yet for this article.
March 2006: Journal of the American Osteopathic Association
https://www.readbyqxmd.com/read/16564934/a-multicenter-randomized-double-blind-placebo-controlled-dose-ranging-study-of-ast-120-kremezin-in-patients-with-moderate-to-severe-ckd
#14
RANDOMIZED CONTROLLED TRIAL
Gerald Schulman, Rajiv Agarwal, Muralidhar Acharya, Tomas Berl, Samuel Blumenthal, Nelson Kopyt
BACKGROUND: AST-120 (Kremezin; Kureha Chemical Industry Co Ltd, Tokyo, Japan) is an orally administered adsorbent showing adsorption ability superior to activated charcoal for certain organic compounds known to be precursors of substances that accumulate in patients with chronic kidney disease (CKD) and that are believed to accelerate the decline in kidney function. AST-120 is approved in Japan for prolonging time to hemodialysis therapy and improving uremic symptoms in patients with CKD...
April 2006: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/16461961/cardiovascular-outcomes-in-high-risk-hypertensive-patients-stratified-by-baseline-glomerular-filtration-rate
#15
RANDOMIZED CONTROLLED TRIAL
Mahboob Rahman, Sara Pressel, Barry R Davis, Chuke Nwachuku, Jackson T Wright, Paul K Whelton, Joshua Barzilay, Vecihi Batuman, John H Eckfeldt, Michael A Farber, Stanley Franklin, Mario Henriquez, Nelson Kopyt, Gail T Louis, Mohammad Saklayen, Carole Stanford, Candace Walworth, Harry Ward, Thomas Wiegmann
BACKGROUND: Chronic kidney disease is common in older patients with hypertension. OBJECTIVE: To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR...
February 7, 2006: Annals of Internal Medicine
https://www.readbyqxmd.com/read/15928338/slowing-progression-along-the-renal-disease-continuum
#16
REVIEW
Nelson P Kopyt
Patients in whom nephropathy develops as a result of hypertension or diabetes mellitus are more likely to die of cardiovascular disease (CVD) than of kidney disease. An early sign of impending nephropathy is microalbuminuria, defined as urinary excretion of albumin at a rate of 28.8 mg/24 h to 288 mg/24 h. Microalbuminuria is a marker of endothelial dysfunction, vascular injury, and renal disease and CVD, and it is associated with increased risk for myocardial infarction. Oxidative stress and endothelial dysfunction are unifying factors mediated by the renin-angiotensin system in renal disease and CVD...
April 2005: Journal of the American Osteopathic Association
https://www.readbyqxmd.com/read/15851647/renal-outcomes-in-high-risk-hypertensive-patients-treated-with-an-angiotensin-converting-enzyme-inhibitor-or-a-calcium-channel-blocker-vs-a-diuretic-a-report-from-the-antihypertensive-and-lipid-lowering-treatment-to-prevent-heart-attack-trial-allhat
#17
RANDOMIZED CONTROLLED TRIAL
Mahboob Rahman, Sara Pressel, Barry R Davis, Chuke Nwachuku, Jackson T Wright, Paul K Whelton, Joshua Barzilay, Vecihi Batuman, John H Eckfeldt, Michael Farber, Mario Henriquez, Nelson Kopyt, Gail T Louis, Mohammad Saklayen, Carol Stanford, Candace Walworth, Harry Ward, Thomas Wiegmann
BACKGROUND: This study was performed to determine whether, in high-risk hypertensive patients with a reduced glomerular filtration rate (GFR), treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of renal disease outcomes compared with treatment with a diuretic. METHODS: We conducted post hoc analyses of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertensive participants 55 years or older with at least 1 other coronary heart disease risk factor were randomized to receive chlorthalidone, amlodipine, or lisinopril for a mean of 4...
April 25, 2005: Archives of Internal Medicine
https://www.readbyqxmd.com/read/15136305/the-prevalence-of-reduced-glomerular-filtration-rate-in-older-hypertensive-patients-and-its-association-with-cardiovascular-disease-a-report-from-the-antihypertensive-and-lipid-lowering-treatment-to-prevent-heart-attack-trial
#18
Mahboob Rahman, Clinton D Brown, Josef Coresh, Barry R Davis, John H Eckfeldt, Nelson Kopyt, Andrew S Levey, Chuke Nwachuku, Sara Pressel, Efrain Reisin, Candace Walworth et al.
BACKGROUND: The prevalence of reduced glomerular filtration rate (GFR) in older hypertensive patients and the relationship between level of GFR and cardiovascular disease (CVD) and its risk factors are not well known. METHODS: We evaluated baseline renal function in 40 514 hypertensive patients 55 years or older who were enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). We used the simplified Modification of Diet in Renal Disease study equation to estimate GFR and examined the prevalence of CVD in patients with different levels of GFR...
May 10, 2004: Archives of Internal Medicine
https://www.readbyqxmd.com/read/14458355/-experience-with-the-application-of-oxyhemometry-in-the-study-of-the-effect-of-general-vibrations-on-the-human-organism
#19
N Ia KOPYT
No abstract text is available yet for this article.
1961: Trudy Leningradskogo Sanitarno-gigienicheskogo Meditsinskogo Instituta
https://www.readbyqxmd.com/read/11978900/risk-factors-for-nephrotoxicity-in-elderly-patients-receiving-once-daily-aminoglycosides
#20
D Raveh, M Kopyt, Y Hite, B Rudensky, M Sonnenblick, A M Yinnon
BACKGROUND: There remain concerns about the safety of once-daily dosing of aminoglycosides (AGs) in the elderly. AIM: To assess the safety of once-daily AGs in elderly patients and evaluate possible risk factors for nephrotoxicity. DESIGN: Prospective, non-interventional surveillance study. METHODS: All patients receiving AGs were monitored over 4 months. Clinicians determined the AG dose for each patient after estimating patient weight and calculating creatinine clearance (CrCl) using the Cockcroft-Gault formula...
May 2002: QJM: Monthly Journal of the Association of Physicians
keyword
keyword
95006
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"